<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="MinionPro" color="#231f20"/>
	<fontspec id="1" size="12" family="Minion-Black" color="#231f20"/>
	<fontspec id="2" size="10" family="MinionMath" color="#231f20"/>
	<fontspec id="3" size="7" family="MinionMath-Capt" color="#231f20"/>
<text top="44" left="51" width="5" height="10" font="0">2</text>
<text top="44" left="397" width="152" height="10" font="0">International Journal of Breast Cancer</text>
<text top="74" left="66" width="225" height="10" font="0">The therapeutic response to any treatment provided</text>
<text top="85" left="51" width="240" height="10" font="0">depends not only on the physiological actions of the treat-</text>
<text top="97" left="51" width="240" height="10" font="0">ment but also on the cultural, social, psychological, and</text>
<text top="108" left="51" width="240" height="10" font="0">physical conditions of each patient. One of these components,</text>
<text top="119" left="51" width="240" height="10" font="0">which may influence the therapeutic response, is the quality</text>
<text top="131" left="51" width="240" height="10" font="0">of life. According to the World Health Organization (WHO)</text>
<text top="142" left="51" width="240" height="10" font="0">quality of life is defined as “individuals” perception of their</text>
<text top="153" left="51" width="240" height="10" font="0">position in life in the context of culture, value systems</text>
<text top="165" left="51" width="240" height="10" font="0">in which they live in relation to their goals, expectations,</text>
<text top="176" left="51" width="240" height="10" font="0">standards, and concerns [15]. For patients with breast cancer,</text>
<text top="187" left="51" width="240" height="10" font="0">quality of life assessment will approach the way they experi-</text>
<text top="199" left="51" width="240" height="10" font="0">ence changes caused by the disease as well as the positive or</text>
<text top="210" left="51" width="240" height="10" font="0">negative influence that the treatment will have on their lives</text>
<text top="222" left="51" width="32" height="10" font="0">[16–23].</text>
<text top="233" left="66" width="225" height="10" font="0">In this context, this study aims to evaluate QOL as a</text>
<text top="244" left="51" width="240" height="10" font="0">predictor of treatment response in women undergoing CPT</text>
<text top="256" left="51" width="240" height="10" font="0">in the treatment of upper limb lymphoedema after axillary</text>
<text top="267" left="51" width="75" height="10" font="0">lymphadenectomy.</text>
<text top="314" left="51" width="130" height="11" font="1"><b>2. Materials and Methods</b></text>
<text top="335" left="51" width="240" height="10" font="0">A randomised clinical trial was conducted in women with</text>
<text top="347" left="51" width="240" height="10" font="0">secondary treatment of breast cancer lymphoedema. The</text>
<text top="358" left="51" width="208" height="10" font="0">study methodology has been previously detailed [9].</text>
<text top="370" left="66" width="225" height="10" font="0">In order to perform the study, 57 women referred for</text>
<text top="381" left="51" width="240" height="10" font="0">unilateral axillary dissection, with a difference between the</text>
<text top="392" left="51" width="240" height="10" font="0">upper limbs greater than three centimeters in circumference</text>
<text top="404" left="51" width="240" height="10" font="0">at one point at least, who were not undergoing chemotherapy</text>
<text top="415" left="51" width="240" height="10" font="0">or adjuvant radiotherapy and showed no heart disease or sys-</text>
<text top="426" left="51" width="240" height="10" font="0">temic decompensated hypertension, were included. Women</text>
<text top="438" left="51" width="240" height="10" font="0">were excluded if they had surgery less than six months</text>
<text top="449" left="51" width="240" height="10" font="0">previously, were diagnosed with preoperative lymphoedema,</text>
<text top="460" left="51" width="240" height="10" font="0">showed signs of inflammation in the swollen limb, had a</text>
<text top="472" left="51" width="240" height="10" font="0">history of allergic reaction to the material used for compres-</text>
<text top="483" left="51" width="240" height="10" font="0">sion bandaging, had active locoregional or distant disease,</text>
<text top="495" left="51" width="240" height="10" font="0">or had been undergoing treatment for lymphoedema with</text>
<text top="506" left="51" width="197" height="10" font="0">compression bandaging for the last three months.</text>
<text top="517" left="66" width="225" height="10" font="0">For the treatment of lymphoedema, all patients under-</text>
<text top="529" left="51" width="240" height="10" font="0">went complex physical therapy (skin care, compression ban-</text>
<text top="540" left="51" width="240" height="10" font="0">daging, exercises, and home orientations), with or without</text>
<text top="551" left="51" width="111" height="10" font="0">manual lymphatic drainage.</text>
<text top="563" left="66" width="225" height="10" font="0">The main outcome (therapeutic response) was considered</text>
<text top="574" left="51" width="240" height="10" font="0">to be the percentage reduction in excess limb volume between</text>
<text top="586" left="51" width="240" height="10" font="0">the beginning and the end of treatment (end of compressive</text>
<text top="597" left="51" width="215" height="10" font="0">bandaging, occurring in about 4 weeks), calculated by</text>
<text top="595" left="268" width="23" height="13" font="2">(𝐼𝑉 −</text>
<text top="606" left="51" width="60" height="13" font="2">𝐹𝑉/𝐼𝑉) ∗ 100</text>
<text top="608" left="111" width="24" height="10" font="0">, with</text>
<text top="606" left="139" width="11" height="13" font="2">𝐼𝑉</text>
<text top="608" left="154" width="119" height="10" font="0">being the initial volume and</text>
<text top="606" left="278" width="13" height="13" font="2">𝐹𝑉</text>
<text top="620" left="51" width="212" height="10" font="0">the final volume. The estimated volume of the limb (</text>
<text top="617" left="263" width="7" height="13" font="2">𝑉</text>
<text top="620" left="270" width="21" height="10" font="0">) was</text>
<text top="631" left="51" width="240" height="10" font="0">obtained from the circumference. The measures for each</text>
<text top="642" left="51" width="108" height="10" font="0">point which were used were</text>
<text top="640" left="161" width="33" height="13" font="2">𝑉 = ℎ ∗</text>
<text top="642" left="195" width="3" height="10" font="0">(</text>
<text top="640" left="198" width="7" height="13" font="2">𝐶</text>
<text top="639" left="205" width="3" height="9" font="3">2</text>
<text top="642" left="211" width="6" height="10" font="0">+</text>
<text top="640" left="218" width="17" height="13" font="2">𝐶∗𝑐</text>
<text top="642" left="237" width="6" height="10" font="0">+</text>
<text top="640" left="245" width="4" height="13" font="2">𝑐</text>
<text top="639" left="249" width="3" height="9" font="3">2</text>
<text top="642" left="253" width="10" height="10" font="0">)/(</text>
<text top="640" left="263" width="22" height="13" font="2">𝜋∗12</text>
<text top="642" left="285" width="6" height="10" font="0">),</text>
<text top="654" left="51" width="34" height="10" font="0">in which</text>
<text top="651" left="87" width="7" height="13" font="2">𝑉</text>
<text top="654" left="96" width="135" height="10" font="0">is the volume of the limb segment,</text>
<text top="651" left="233" width="7" height="13" font="2">𝐶</text>
<text top="654" left="241" width="15" height="10" font="0">and</text>
<text top="651" left="258" width="4" height="13" font="2">𝑐</text>
<text top="654" left="264" width="27" height="10" font="0">are the</text>
<text top="665" left="51" width="126" height="10" font="0">circumferences at each end, and</text>
<text top="663" left="178" width="5" height="13" font="2">ℎ</text>
<text top="665" left="185" width="105" height="10" font="0">is the distance between the</text>
<text top="676" left="51" width="66" height="10" font="0">circumferences (</text>
<text top="674" left="117" width="7" height="13" font="2">𝐶</text>
<text top="676" left="124" width="6" height="10" font="0">).</text>
<text top="688" left="66" width="225" height="10" font="0">Descriptive variables were collected, such as age, body</text>
<text top="699" left="51" width="240" height="10" font="0">mass index (BMI), time to onset postoperative lymphoe-</text>
<text top="711" left="51" width="240" height="10" font="0">dema, excess volume in the segment, duration of chronic</text>
<text top="722" left="51" width="240" height="10" font="0">lymphoedema, and the number of infections in the limb with</text>
<text top="733" left="51" width="59" height="10" font="0">lymphoedema.</text>
<text top="74" left="324" width="225" height="10" font="0">As the main predictor variable, the mean score of quality</text>
<text top="85" left="309" width="240" height="10" font="0">of life was considered, measured at study entry. Quality</text>
<text top="97" left="309" width="240" height="10" font="0">of life was assessed by the EORTC QLQ-C30 and BR23,</text>
<text top="108" left="309" width="240" height="10" font="0">both validated by the Brazilian population [16]. QLQ-C30</text>
<text top="119" left="309" width="240" height="10" font="0">is a multidimensional questionnaire designed to assess the</text>
<text top="131" left="309" width="240" height="10" font="0">psychological and social functioning of patients with cancer.</text>
<text top="142" left="309" width="240" height="10" font="0">It is made up of 30 questions that assess five functional scales</text>
<text top="153" left="309" width="240" height="10" font="0">(physical, functional, cognitive, emotional, and social role),</text>
<text top="165" left="309" width="240" height="10" font="0">three symptom scales (fatigue, pain, nausea, and vomiting),</text>
<text top="176" left="309" width="240" height="10" font="0">and quality of life scales and overall health. QLQ-BR23</text>
<text top="187" left="309" width="240" height="10" font="0">intends to specifically evaluate the effects of treatment in</text>
<text top="199" left="309" width="240" height="10" font="0">patients with breast cancer. It consists of 23 questions divided</text>
<text top="210" left="309" width="240" height="10" font="0">into two scales: physical functioning and symptoms. The</text>
<text top="222" left="309" width="240" height="10" font="0">functional scale is divided into ranges of body image, sexual</text>
<text top="233" left="309" width="240" height="10" font="0">function, sexual satisfaction, and future perspective. The sec-</text>
<text top="244" left="309" width="240" height="10" font="0">ond level consists of the subscales: adverse effects of systemic</text>
<text top="256" left="309" width="240" height="10" font="0">therapy, breast symptoms, and arm symptoms. QLQ-C30 and</text>
<text top="267" left="309" width="240" height="10" font="0">BR23 have a scale ranging from 0 to 100, in which 0 is the</text>
<text top="278" left="309" width="240" height="10" font="0">worst health status and 100 the best of health, except for</text>
<text top="290" left="309" width="240" height="10" font="0">the symptom scales in which higher scores represent more</text>
<text top="301" left="309" width="240" height="10" font="0">symptoms and worse quality of life. For statistical analysis, the</text>
<text top="312" left="309" width="240" height="10" font="0">symptom scale was reversed so that higher scores represent</text>
<text top="324" left="309" width="97" height="10" font="0">better quality of life [15].</text>
<text top="335" left="324" width="225" height="10" font="0">The descriptive analysis of the study population was</text>
<text top="347" left="309" width="240" height="10" font="0">performed by using measures of central tendency and dis-</text>
<text top="358" left="309" width="240" height="10" font="0">persion. To evaluate the changes in excess volume before</text>
<text top="369" left="309" width="240" height="10" font="0">and after treatment, we performed the Wilcoxon signed-rank</text>
<text top="381" left="309" width="166" height="10" font="0">test, considered statistically significant at</text>
<text top="378" left="478" width="39" height="13" font="2">𝑝 &lt; 0.05</text>
<text top="381" left="517" width="31" height="10" font="0">. Linear</text>
<text top="392" left="309" width="240" height="10" font="0">regression was performed to evaluate the association between</text>
<text top="403" left="309" width="240" height="10" font="0">the scores of the domains of quality of life before treatment</text>
<text top="415" left="309" width="240" height="10" font="0">and the therapeutic response. The statistical package SPSS</text>
<text top="426" left="309" width="118" height="10" font="0">20.0 was used for all analyses.</text>
<text top="438" left="324" width="225" height="10" font="0">The project was approved by the Ethics Committee in</text>
<text top="449" left="309" width="240" height="10" font="0">Research of the National Cancer Institute (INCA) under</text>
<text top="460" left="309" width="240" height="10" font="0">registration number 011/07 and was in accordance with</text>
<text top="472" left="309" width="240" height="10" font="0">the Helsinki Declaration of 1975, as revised in 2008. All</text>
<text top="483" left="309" width="188" height="10" font="0">participants signed the informed consent form.</text>
<text top="519" left="309" width="49" height="11" font="1"><b>3. Results</b></text>
<text top="540" left="309" width="240" height="10" font="0">The study included 57 women. At inclusion in the study, the</text>
<text top="551" left="309" width="240" height="10" font="0">average age of the study population was 63 years (SD 10.02),</text>
<text top="563" left="309" width="240" height="10" font="0">mostly overweight and obese. The average time after surgery</text>
<text top="574" left="309" width="240" height="10" font="0">until the development of lymphoedema was 37 months. At</text>
<text top="586" left="309" width="240" height="10" font="0">the beginning of treatment, lymphoedema was present for</text>
<text top="597" left="309" width="240" height="10" font="0">a median of 61 months (5 years). At baseline, the mean</text>
<text top="608" left="309" width="240" height="10" font="0">excess volume (EV) between the upper limbs was 776.16 mL,</text>
<text top="620" left="309" width="240" height="10" font="0">corresponding to a percentage excess volume (PEV) of 44.2%</text>
<text top="631" left="309" width="36" height="10" font="0">(Table 1).</text>
<text top="642" left="324" width="225" height="10" font="0">After treatment, the absolute decrease in statistically</text>
<text top="654" left="309" width="240" height="10" font="0">significant excess volume between the upper limbs of 282 mL</text>
<text top="665" left="309" width="194" height="10" font="0">was observed, representing a reduction of 15% (</text>
<text top="663" left="503" width="43" height="13" font="2">𝑝 = 0.001</text>
<text top="665" left="545" width="3" height="10" font="0">)</text>
<text top="676" left="309" width="37" height="10" font="0">(Table 2).</text>
<text top="688" left="324" width="225" height="10" font="0">In measuring quality of life for the functional scale of</text>
<text top="699" left="309" width="240" height="10" font="0">the EORTC QLQ-C30 questionnaire, the worst scores for</text>
<text top="711" left="309" width="240" height="10" font="0">emotional function (55 points) and better social function</text>
<text top="722" left="309" width="240" height="10" font="0">(89 points) were observed. In the symptom scales, pain</text>
<text top="733" left="309" width="240" height="10" font="0">presented the worst average (66 points), followed by fatigue</text>
</page>
</pdf2xml>
